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Abstract
Background: Obesity is often comorbid with depression and individuals with this comorbidity
fare worse in behavioral weight loss treatment. Treating depression directly prior to behavioral
weight loss treatment might bolster weight loss outcomes in this population, but this has not yet
been tested in a randomized clinical trial.
Methods and design: This randomized clinical trial will examine whether behavior therapy for
depression administered prior to standard weight loss treatment produces greater weight loss than
standard weight loss treatment alone. Obese women with major depressive disorder (N = 174)
will be recruited from primary care clinics and the community and randomly assigned to one of the
two treatment conditions. Treatment will last 2 years, and will include a 6-month intensive
treatment phase followed by an 18-month maintenance phase. Follow-up assessment will occur at
6-months and 1- and 2 years following randomization. The primary outcome is weight loss. The
study was designed to provide 90% power for detecting a weight change difference between
conditions of 3.1 kg (standard deviation of 5.5 kg) at 1-year assuming a 25% rate of loss to follow-
up. Secondary outcomes include depression, physical activity, dietary intake, psychosocial variables
and cardiovascular risk factors. Potential mediators (e.g., adherence, depression, physical activity
and caloric intake) of the intervention effect on weight change will also be examined.
Discussion: Treating depression before administering intensive health behavior interventions
could potentially boost the impact on both mental and physical health outcomes.
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Background
Obesity is a serious public health threat in the United
States with 32.2% of the population affected [1]. Links
between obesity and depression have been observed in
clinical and epidemiological studies, particularly among
women. In one clinic sample, 34% of treatment-seeking
obese women were found to have major depressive disor-
der (MDD) [2]. This is concerning because depression is
associated with worse outcomes in behavioral weight loss
treatment [2]. However, the vast majority of randomized
clinical trials testing obesity treatments either exclude
individuals who are clinically depressed [3,4] or do not
assess depression status [5-9]; thus evidence for the effi-
cacy of behavioral weight loss treatments for depressed,
obese individuals is lacking. Given the concurrence of
depression with obesity and the difficulty depressed indi-
viduals have losing weight, behavioral weight loss treat-
ments that address the unique needs of this population
are needed.
A comorbid relationship between obesity and depression
suggests that the two conditions may have related mecha-
nistic pathways, which could have implications for treat-
ment. Obesity is associated with anhedonia [10], a
reduced capacity to experience pleasure, which is also a
primary symptom of MDD [11,12]. Obese women appear
less able to elicit pleasure from ordinarily pleasurable
experiences compared to their lean counterparts [10].
When comorbid with depression, obesity may be in part
attributable to maladaptive mood regulatory habits
involving overeating and inactivity. Targeting weight loss
through dieting could thwart this mood regulatory proc-
ess by facilitating feelings of deprivation, causing com-
pensatory overconsumption and worsened depressive
symptoms. Treatments for depression in the context of
obesity should directly address the links between mood,
eating, and active versus sedentary behaviors, but tradi-
tional behavioral weight loss treatments were not neces-
sarily designed to target this combination of issues, and
neither were depression psychotherapies. However,
behavioral treatments for depression that address mala-
daptive mood regulatory habits may be helpful in the con-
text of obesity, to the extent that eating behavior and
inactivity can be specifically targeted.
A treatment emanating from behavioral theory, behavio-
ral activation [12,13], aims to increase exposure to the
positive consequences of healthy behavior, for the pur-
pose of increasing engagement in healthy behaviors,
reducing engagement in depressive behaviors and
decreasing avoidance behavior[13,14]. The focus of
behavioral activation on increasing healthy activity and
eliminating avoidance is appropriate to the treatment
goals of depression and obesity. Weight loss could be
facilitated by increasing an individual's arsenal of mood
regulatory behaviors to break an over reliance on eating
for coping with negative moods, and to gradually adopt
more physically active coping behaviors. Avoidance by
obese patients can take the form of excessive eating or pro-
longed sedentary activities that prevent engagement in
other more reinforcing and active aspects of life. Increas-
ing coping behaviors that are physically active or incom-
patible with eating may help to reduce avoidance
behavior, depressive symptoms, and ultimately weight.
The efficacy of behavioral activation for depression has
been demonstrated in a variety of populations and set-
tings [15-18]. In a pilot study, our group demonstrated
reductions in depression, good treatment adherence, and
high treatment satisfaction for an intervention that deliv-
ered behavioral activation simultaneously with a brief
nutrition counseling intervention [19]. However, in that
study, average weight loss was modest and the greatest
losses were observed in the latter weeks of treatment, after
depressive symptoms had improved. Improving depres-
sive symptoms prior to an intensive dietary intervention
might be a more effective sequence of treatment delivery
for weight loss outcomes in women with depression.
Research Goals
The present study aims to compare the efficacy of a
sequential two-part treatment, behavioral activation for
depression followed by standard weight loss treatment
(BA), to standard weight loss treatment that is not accom-
panied by depression counseling (ST) on weight change
in depressed, obese women. The primary hypothesis is
that participants in the BA condition will achieve greater
weight loss than participants in the ST condition at 6-
months and 1- and 2-year follow-up. Secondary research
goals include comparing groups on change in depression,
physical activity, daily caloric intake, psychosocial varia-
bles (emotional eating, quality of life), and cardiovascular
risk factors (blood pressure, serum lipids, C-reactive pro-
tein and waist circumference) at 6-months and 1- and 2-
year follow-up. Additionally, potential mediators (treat-
ment adherence, depression, physical activity, caloric
intake) of the intervention effect on weight change will be
tested.
Methods
Study Design
This is a randomized controlled trial where obese partici-
pants with MDD are randomized to one of two treatment
conditions: BA or ST. All procedures and material were
approved by the University of Massachusetts Medical
School's Internal Review Board.
Eligibility Criteria
Women between the ages of 21 and 65 years old who
meet criteria for obesity and MDD will be recruited. TableBMC Psychiatry 2008, 8:77 http://www.biomedcentral.com/1471-244X/8/77
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1 summarizes the inclusion and exclusion criteria. Exclu-
sion criteria were derived to: 1) minimize adverse effects
of the intervention (e.g., physical limitations, does not
receive physician clearance); 2) decrease error associated
with the primary outcomes (e.g., taking weight loss med-
ication or medications that influence weight); 3) prevent
missing data (e.g., plans to move, no telephone) and 4)
prevent participants who may require more intensive or
more appropriate psychological intervention from enroll-
ing in the study (e.g., active suicidal ideation, bipolar dis-
order, psychotic disorder). Participants who have been
taking antidepressant medications (ADM) for more than
3 months and have no plans to change the regimen will
be eligible. While participants who are on ADM will not
be excluded, those in psychotherapy will be excluded
because of potential conflicting therapeutic goals and pos-
sible contamination in the no therapy condition.
Recruitment
A computerized Patient Health Care Information System
used in the University of Massachusetts Memorial (UMM)
primary care clinics will identify participants who are
potentially eligible using age, female gender, and body
mass index ranges. Candidates will be contacted via an
introductory letter signed by their primary care physician
and the principal investigator (PI). Candidates will be
given the opportunity to opt out by phone, or be phoned
for an initial telephone screening two weeks after receiv-
ing the letter. Participants will also be recruited from the
community via media outlets, the medical center intranet,
and community flyers. Minority populations will be tar-
geted by distributing flyers to businesses and health clin-
ics that serve predominately minority populations and
using advertisements in media outlets that have a large
minority audience base. Free seminars about women's
health will also be conducted at local businesses, commu-
nity organizations, and churches to facilitate recruitment.
Screening Process and Informed Consent
Initial eligibility will be assessed by phone and pre-eligi-
ble participants will be invited to the study visit for a
screening appointment where informed consent will be
obtained and eligibility will be further assessed. The Struc-
tured Clinical Interview for the Diagnostic and Statistical
Manual-IV [20] will be administered to confirm the diag-
nosis of MDD. Eligible participants will then complete a
baseline assessment visit, for which they will receive $50
(see Table 2 for the list of screening and baseline meas-
ures). Those not qualifying will receive referrals to weight
loss and/or depression treatment, when applicable.
Randomization
After completing the baseline visit and 24 hour diet and
physical activity recalls, participants will be randomized
to the BA or ST condition. Participants will be stratified
into 4 strata of possible combinations of ADM (2: present,
absent) × MDD severity (2: Hamilton Rating Scale for
Depression (HRSD); [21]: 13–18, 19–24) at baseline.
Table 1: Participant eligibility and exclusion criteria.
Eligibility Criteria
Female
Major depressive disorder
Age: 21–65 years
Body mass index: 30–40 kg/m2
Exclusion Criteria
Unable/unwilling to provide informed consent
Plans to move out of area during study period
Smoker
Bipolar, psychotic, or post-traumatic stress disorder, bulimia
Severe depression: HDRS > 24 or BDI-II >29
Type 1 or 2 diabetes
Had or plans to have bariatric surgery
No telephone
Unable to walk unaided or cannot walk 1/4 mile without stopping
Does not have written clearance from primary care provider for study participation
Has a medical condition which precludes dietary changes
Has medical conditions likely to limit lifespan
Taking prescription weight loss medications
Initiated anti-depressant medication within the previous 6 weeks
Active suicidal ideation
Psychiatric hospitalization in the past 12 months
Currently in psychotherapy
Taking mood stabilizers, anti-psychotic medication or medications known to affect appetite and/or weight
Note. HRSD = Hamilton Rating Scale for Depression; BDI-II = Beck Depression Inventory-II.BMC Psychiatry 2008, 8:77 http://www.biomedcentral.com/1471-244X/8/77
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Within each strata, participants will be randomized to the
two conditions in randomly permuted blocks of size 3
and 6 using the ralloc program in Stata [22]. This will
ensure that the distribution of ADM status and MDD
severity are approximately similar between two study con-
ditions.
Outcomes and Study Measures
The main study outcome will be body weight measured
using the digital Tronix scale, with the participant wearing
only light clothing and no shoes. Body weight will be
measured at every study visit, but analyses will focus pri-
marily on change in body weight from baseline to the 6-
months and 1- and 2-year follow-up.
Secondary outcomes include depression (HRSD and Beck
Depression Inventory-II (BDI-II); [23]), physical activity
and dietary intake, other psychosocial variables (emo-
tional eating, quality of life), and cardiovascular risk fac-
tors (blood pressures, serum lipids, C-reactive protein) at
6-months and 1- and 2-year follow-up.
Treatment adherence data will also be collected at all
assessment time points to examine possible mechanisms
of the effect of the BA intervention on body weight. Addi-
tional potential mediators include caloric intake, physical
activity and depression (see Table 2 for a complete list of
study measures and the timing of these measures).
Intervention
Both ST and BA conditions will involve an Intensive Treat-
ment and a Maintenance phase. The Intensive Treatment
phase will last 6-months and involve 26 sessions. Ten ses-
sions will be 1-hour individual visits, and 16 sessions will
be 1.5-hour group behavioral weight loss visits conducted
by a registered dietitian or exercise physiologist. The tim-
ing of the individual and group visits varies between the
two conditions. In the BA condition, participants will
begin with 10 weekly individual visits of behavior therapy
for treatment of depression, with the initial group behav-
ioral weight loss visits starting on week 9. Participants in
the ST condition will begin both the group behavioral
weight loss visits and individual health education visits on
week 1 (see Tables 3 and 4 for the timing of individual
and group sessions in each condition) for two reasons.
First, paralleling the BA condition (i.e., first 8-weeks of
individual visits of health education attention control
only) could lead to differential attrition rates since ST par-
ticipants may not stay engaged when active treatment is
delayed for 8 weeks. Second, this approach is also more
consistent with usual care, in which participants would be
enrolled and begin treatment immediately.
The 18 month Maintenance phase will consist of 6
monthly 90-minute group sessions and 6 monthly 20-
minute counseling phone calls by their therapist or health
education counselor, depending on their condition
Table 2: List of measures and frequency.
Screening Baseline Month 6 Year 1 Year 2
Structured Clinical Interview for DSM-IV X X X X
Hamilton Rating Scale for Depression X X X X X
Beck Depression Inventory X X X X X
Medical History Questionnaire X X X X
Brief Medication Questionnaire X X X X
Body weight XX X X X
Height X
Waist and hip circumference X X X X
Blood pressure XX X X
Fasting blood: Cholesterol, LDL, HDL, triglycerides, C-reactive protein X X X X
Three 24-hour dietary recalls X X X X
Three 24-hour physical activity recalls X X X X
Fawcett-Clark Hedonic Capacity X X X X
Short-form 36 Health Survey X X X X
Dutch Eating Behavior Questionnaire X X X X
Paffenbarger Physical Activity Questionnaire X X X X
Environmental Reward Observational Scale X X X X
Note. DSM-IV = Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; LDL = low-density lipoprotein; HDL = high-density 
lipoprotein
Table 3: Distribution of treatment sessions by condition during 
the first 12 weeks of the 6-month Intensive Treatment phase.
Week 1 2345 6789 1 01 11 2
ST I / GGGGI / GGGGG G I G
BA I IIII IIII / G I / G GG
Note. ST = Standard treatment; BA = Behavioral Activation; I = 
Individual visit; G = Group visitBMC Psychiatry 2008, 8:77 http://www.biomedcentral.com/1471-244X/8/77
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assignment. Then, participants will receive 20-minute
counseling phone calls once every 3 months for one year.
All visits in both phases will be audiotaped for quality
assurance.
BA Condition
Behavioral Weight Loss
Behavioral weight loss groups will be based on the Diabe-
tes Prevention Program (DPP) [24]. A team dietitian will
lead 8 of the 16 Intensive Treatment sessions and 3 of the
6 Maintenance sessions. During the Intensive Treatment
phase, participants will receive extensive instruction and
practice in self-monitoring of caloric and fat intake. Partic-
ipants will receive calorie goals that are estimated to pro-
duce a weight loss of 1–2 pounds per week [i.e., (starting
weight × 12) – 500 kcal]. All participants will be given a
goal for daily total fat intake in grams that is based on
25% of total calories from total fat. Participants will self-
monitor fat and calories daily for 18 weeks and then one
week every month for the following 6-months. Partici-
pants will be encouraged to work slowly toward regular
self-monitoring, beginning with 2–3 days and working up
to 5–7 days over the first 16 weeks. Participants who have
difficulty tracking their dietary intake and physical activity
will be given modest goals with suggestions to increase
tracking gradually. Participants will receive assistance to
individualize the study diet based on their usual dietary
habits. Participants will be given diet diaries for self-mon-
itoring, the "DPP Fat Counter," a guide of nutrition infor-
mation for hundreds of foods, and multiple resources for
obtaining additional information on areas of concern,
including eating out and other social activities and reci-
pes. Self-monitoring diaries will be reviewed by the regis-
tered dietitian and returned with suggestions for change
and positive feedback. Although the original DPP proto-
col is based on a low-fat diet, this has been updated to
include suggestions to decrease detrimental fats preferen-
tially, namely saturated and trans-fats, and to substitute
whole grains in place of refined carbohydrate foods to
match current dietary recommendations put forth by the
United States Department of Agriculture Dietary Guide-
lines for Americans and the American Heart Association
Dietary Guidelines [25-27].
The exercise physiologist will lead 8 of the 16 Intensive
Treatment group sessions and 3 of the 6 Maintenance ses-
sions. Participants will work toward the goal of 60 min-
utes of moderate physical activity on 5 days/week. While
walking will be encouraged and pedometers provided,
participants will also be encouraged to increase their
engagement in any of their preferred physical activities.
Participants will be lead through a brief moderate physical
activity in each session following didactic content. Exam-
ples include group walks, pilates, aerobics, and yoga. See
Table 5 for the complete list of group topics.
Behavioral Activation
The treatment protocol for individual sessions is based on
brief behavioral activation treatment as developed by
Lejuez and colleagues [14]. Each session will emphasize
behavioral activation strategies for depression and how
the behavioral activation approach can lead to a more
enriching active lifestyle (See Table 6 for individual ses-
sion content) [14,28,29]. A Master's or doctoral level
counselor will conduct all 10 of the individual counseling
sessions and all 10 of the 20-min telephone sessions. A
total of 20 sessions (in person and telephone) are devoted
to behavioral activation strategies because efficacy with
this protocol has been established in 20–24 sessions [28].
Participants will first be educated about how depression
affects them from a behavioral activation perspective.
Then, the following behavioral activation skills will be
taught: 1) self-monitoring of daily activities and moods;
2) identification of relationships between daily activities
and mood; 3) behavioral contracting; 4) identification of
values and goals within a variety of life areas including
relationships, employment/career, hobbies/recreation,
physical/health issues, and spirituality; 5) developing an
activity hierarchy in which 15 activities consistent with
life goals are rated ranging from "easiest" to "most diffi-
cult" to accomplish; 6) regular completion of a master
activity log and behavioral checkout to monitor progress
as the participant moves through the hierarchy in a pro-
gressive manner, moving from the easier behaviors to the
more difficult; 7) recognition of avoidance patterns and
how they affect mood; and 8) continued assessment of
progress and modification of goals as necessary. Earlier
sessions will be used to introduce these components and
later sessions will include both strategies for increasing
success in achieving reasonable life activity goals and for
modifying unrealistic or overly difficult activity goals.
Behavioral activation for depression is not meant to spe-
cifically target weight loss as a goal. Instead, it will address
the processes underlying weight dysregulation, including
mood regulatory eating, avoidance, and inactivity.
Addressing these factors in advance of dietary and physi-
Table 4: Distribution of treatment sessions by condition during 
the second 12 weeks of the 6-month Intensive Treatment phase.
Week 13 14 15 16 17 18 19 20 21 22 23 24
ST IG IG IG IG IG II
BA GGGGGGGGGGGG
Note. ST = Standard treatment; BA = Behavioral Activation; I = 
Individual visit; G = Group visitBMC Psychiatry 2008, 8:77 http://www.biomedcentral.com/1471-244X/8/77
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cal activity prescriptions may be essential to progress
toward weight loss goals during the weight treatment pro-
gram that follows.
During the Maintenance phase, counselors will contact
participants monthly for 20-min phone calls for 6-
months and quarterly for one year. As Lejuez and col-
leagues [14] describe, once participants have progressed
to become more skilled at behavioral activation, sessions
may become shorter and/or administered by phone.
Phone contacts will be used to provide support for contin-
ued progress, reinitiate self-monitoring, recycle through
the activation process when needed, and keep contact
information up-to-date.
ST Condition
Behavioral Weight Loss
Although the timing of the group visits will differ between
conditions, the content of the group weight loss interven-
tion in the ST condition will be identical to the BA condi-
tion as described above.
Attention Control (Health Education)
A health educator with no training in behavior therapy or
psychological counseling will conduct all 10 individual
sessions during the Intensive Treatment phase and all 20-
minute phone calls during the Maintenance phase. Health
education sessions were added to the ST condition to
serve as an attention control for the nonspecific effects of
Table 5: Content of group sessions during Intensive Treatment (16 sessions) and Maintenance (6 monthly sessions) phases.
Session # Group Content
1 D&E Session 1: Welcome to the Lifestyle Balance Program
2 D Session 2: Be a Fat Detective
3 E Session 3: Being Active: A Way of Life (group walk)
4 D Session 4: Three Ways to Eat Less Fat
5 E Session 5: Move Those Muscles
6 D Session 6: Healthy Eating
7 E Session 7: Creating a Cardiovascular Program; Building Motivation
8 D Session 8: Taking Charge of What's Around You
9 E Session 9: Talking Back to Negative Thoughts
10 D Session 10: Tip the Calorie Balance (group walk)
11 E Session 11: The Slippery Slope of Lifestyle Change
12 D Session 12: Problem Solving Diet and Physical Activity
13 E Session 13: Jump Start Your Activity Plan (group walk)
14 D Session 14: Four Keys to Healthy Eating Out
15 E Session 15: You Can Manage Stress
16 E Session 16: Ways to Stay Motivated
M1 D Month 1: Food Cues
M2 E Month 2: Staying Active on Vacation and Holidays (group walk)
M3 D Month 3: Vitamins and Supplements
M4 E Month 4: Muscle Training (group practice)
M5 D Month 5: Food tasting
M6 E Month 6: Maintaining Motivation After the Program
Note. D = dietitian-led group E = exercise physiologist-led group
Table 6: Content of behavioral activation individual sessions during Intensive Treatment phase.
Session # Behavioral Activation Content
1 Getting Started: How depression affects you
2 Create an environment that supports you; behavioral contracting support
3 Activity hierarchies
4 Reviewing Activity Experiments
5 Avoidance As A Habit
6 The Power of ACTION
7 Rumination and Mindfulness
8M o o d  D e p e n d e n c e
9 Progress check: Recycle experiments for difficult behaviors
10 Continued Progress: Behavioral Activation on your ownBMC Psychiatry 2008, 8:77 http://www.biomedcentral.com/1471-244X/8/77
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behavior therapy. An attention control is designed to sim-
ulate a behavioral intervention, providing the same
amount of contact as the individual counseling in the BA
condition, but is not believed to be an effective treatment
for depression [30]. This attention control condition lacks
components of behavioral activation that are considered
integral to its success. The content of the attention control
sessions is designed based on prior research demonstrat-
ing that provision of information is not sufficient to
change behavior [31-37]. Health information about top-
ics relevant to women's health will be discussed. Partici-
pants will select from 19 different health education and
well-being topics including body composition analyses,
menopause, skin health, finances, dressing for different
body shapes, and proper footwear (see Table 7 for the full
list of topics). To enhance attendance, participants will be
informed that the visit will be for a "weigh in" and health
education counseling. The health educator will develop a
supportive relationship with the participant, provide
health education, but will avoid problem solving or coun-
seling with the participant for depression treatment.
When participants have specific questions regarding goals
or seek advice, they will be referred to their group leader.
During the Maintenance phase, health educators will con-
tact participants monthly for 20-minute phone calls for 6
months and quarterly for one year. Calls will be for the
purpose of fostering motivation to attend the 1- and 2-
year follow-ups as well as to provide educational material
on women's health issues.
Participant Safety
All eligible participants must receive permission from
their primary care physician to participate in the study.
Depression safety precautions include having participants
complete a BDI-II at every individual and group visit,
(except when there is an individual and group visit in the
same week) to assess depression levels and suicidality. If a
participant reports active suicidal ideation with intent, she
will be referred for psychiatric treatment and/or escorted
to the Emergency Department at UMM. The PI, a licensed
clinical psychologist, will review depression severity
scores (BDI-II) of all participants on a weekly basis. If a
participant's depression symptoms elevate to 30 or higher
on the BDI-II (i.e., severe depression) during treatment,
alternative treatment will be deemed clinically necessary
and that participant will be referred to the appropriate
service. Participants who remain depressed (BDI-II > 12)
at the end of treatment will receive written materials about
depression treatment options and a list of referrals for
depression treatment services.
To minimize risks associated with increasing physical
activity, intervention personnel will screen participants at
each encounter point to assess symptoms that would
increase the risk of physical activity and to report concerns
as appropriate. In the case of a concern, the study physi-
cian and the participant's primary care physician will be
consulted. The nutritional adequacy of the diet will be
monitored by our senior nutritionist. If there is concern
about a participant's nutrient intake, a report is sent to the
participant's primary care physician with the area of con-
cern highlighted and appropriate advice provided by our
clinical nutritionist.
Safety monitoring procedures are documented in a stand-
ard protocol and overseen by the PI and project director.
Any adverse events are reviewed by the study physician
Table 7: List of topics for standard treatment individual sessions during Intensive Treatment phase.
Session # Standard Treatment Content
1 Body Composition Analyses
2 Vitamins for Women: Making sense out of vitamins
3 Menopause: Your survival guide
4 Breast self-exams: Learn how (and why) to perform a breast self-exam regularly
5 Sexual health
6 Skin health: Have your UV photo taken
7 Bone health
8 Footwear for physical activity: Those aching feet
9 Back pain: Oh, my aching back
10 Heartburn and GERD (gastroesophageal reflux disease)
11 Arthritis
12 Alcohol safety: should I be drinking to my health
13 Dementia: Forget where you put your keys again
14 Heart attack: How do I know if I'm having one
15 Home safety
16 Going green
17 What every woman should know about finances
18 Dress for your body typeBMC Psychiatry 2008, 8:77 http://www.biomedcentral.com/1471-244X/8/77
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within 24 hours. If he deems that the adverse event war-
rants escalation, the data safety monitoring board
(DSMB) will then be notified. Unanticipated adverse
events or anticipated adverse events that require medical
treatment will be reported to the internal review board. All
adverse reactions reported by participants will be docu-
mented by intervention providers and reviewed on a
monthly basis by the PI and project director. Participants
will be referred to their healthcare provider for a medical
evaluation and follow-up as needed or recommended by
the DSMB. The internal review board, the funding agency
and the DSMB will be notified of serious adverse events
within 48 hours.
Retention
A participant tracking system will be used to assure that
participants are contacted on a timely basis to obtain
study data. Participants are also provided a $50 incentive
at baseline, 6-months and 1- and 2-year follow-ups for
completion of data collection visits. If they are unable to
attend, a home visit will be arranged. Following a missed
intervention class, participants will receive class materials
by mail. Regular telephone contact with individual BA
therapists and ST health educators (monthly during the
last 6 months of year 1 and every three months during
year 2) will help to keep participants engaged in the pro-
gram and provide an opportunity to obtain updated con-
tact information. If an individual therapist or health
educator is concerned about a participant withdrawing, he
or she will speak individually with the participant and
attempt to address reasons for disengagement or drop-
out. For the purposes of retention, at least three alternative
contacts, individuals (e.g., family members, friends) who
could provide the participant's contact information if it
changes, are collected.
Sample Size Considerations and Statistical Analyses
Sample Size
This study will randomize 174 participants into two con-
ditions (87 per condition) who will be followed for 2
years. We expect approximately 90% power for detecting
differences in weight between the conditions assuming a
weight change difference of 3.1 kg at 1-year (standard
deviation = 5.5 kg) and a 25% loss-to-follow-up rate. This
projected data for group differences was taken from pilot
data at 6 months and projected to one year based on the
original DPP weight change data. The standard deviation
was a conservative value chosen from a range of successful
lifestyle intervention studies [38-40].
Primary and Secondary Hypotheses-Analysis Plan
The primary outcome compares body weight between the
two randomized groups at 6-months and 1-year follow-
up using an intent-to-treat analysis. Linear mixed mode-
ling, using SAS PROC MIXED [41] will test time and
group interactions to asses whether within-subject change
in body weight differs by condition. Analyses will also be
conducted to examine whether there is a dose-response
relationship between attendance and outcome, where
dose is defined in terms of number of sessions attended.
In addition, we will model percent change in body weight
at 6-, and 12-months using a similar model.
Secondary outcomes will compare the conditions on
depression scores, physical activity, daily caloric intake,
treatment adherence (session completion), quality of life
score, waist circumference, blood pressure, C-reactive pro-
tein and serum lipids at 6-months and 1- and 2-years.
Analyses for these outcomes will be similar to those con-
ducted for body weight. To explore proposed mechanisms
of change, longitudinal associations of body weight and
depressive scores, treatment adherence, and physical
activity will be modeled using structural equation mode-
ling [42]. Reciprocal influences of body weight and other
factors over time will be modeled in structural equation
modeling using nonrecursive models [43]. The two condi-
tions will also be compared on body weight and second-
ary outcomes at the 2-year follow-up relative to baseline
to examine long-term maintenance. The analysis for this
outcome will be similar to those conducted for body
weight at 6 months and 1-year.
Study Operation and Tracking System
The tracking system used for monitoring participant study
activities and providing necessary prompts is based on a
communication system using Lotus Notes software R5
from IBM (Release 5.0.11). Because of its responsiveness
to changes in study participants' data, the Lotus Notes
tracking system functions as a watchdog for the staff, auto-
matically flagging any participant who is nearing a dead-
line for a measurement or intervention session. This
system is ideal for monitoring the progress of study partic-
ipants and interventionists, and alerts the project manager
and other study personnel to all study data collection
points. The software also will be used to gather and store
data that can be shared by individuals both on-site and in
remote locations. This includes 24 hour dietary and phys-
ical activity recall call assignments and the status of these
and other data which are collected at remote sites and
downloaded directly to the Lotus Notes system. It also
provides reports of data such as those from participant
questionnaires and blood test results. Storage of such data
provides instant access to critical information for inter-
vention and data collection. Multiple levels of password
protection are utilized to ensure data security.
Data Management
All study data are entered into computerized data files uti-
lizing: 1) Lotus Notes for participant tracking and inter-
vention data entry, 2) the Nutrition Data System forBMC Psychiatry 2008, 8:77 http://www.biomedcentral.com/1471-244X/8/77
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Research software computer-assisted telephone interview
system for 24 hour recalls, and 3) Snap Surveys for dou-
ble-entry verification of data from paper and pencil forms.
Data sets will be cleaned, verified and archived, and then
read into SAS (version 9.1) data sets, which also are
archived. All analytic and tracking database files are stored
in a secure network drive and backed up at daily basis. On
a weekly, monthly, quarterly and yearly basis complete
backups are made of all database files. One copy is saved
on-site and one off-site. Separate archival databases are
permanently maintained.
At the time of data collection, research assistants will
review participant responses on questionnaires with par-
ticipants present. Skipped or incorrectly addressed items
will be brought to the participant to correct. Data from
pencil and paper forms are entered using a double entry
format. All of the data entry systems employ automatic
checks for values that are out of range or represent errors
of logic. These procedures reduce transcription errors for
hard copy data to close to zero (<0.5%). A random 10%
of all 24 hour recall telephone interviews will be moni-
tored. Monthly exploratory analyses will be conducted to
detect outliers [44].
Treatment Fidelity
Individual Sessions (Behavioral Activation and Health Education)
Treatment fidelity checklists (2 Provider Checklists and 1
Auditor Checklist) were developed to monitor treatment
fidelity. A set of Provider Checklists were developed for
each condition. Interventionists will complete a Provider
Checklist after each session. A random selection stratified
by counselor of 10% of audio-recorded individual ses-
sions will be reviewed and an Auditor Checklist com-
pleted by individuals trained in behavioral activation. The
Auditor Checklist covers treatment objectives from both
health education and behavior therapy for that session.
Perfect treatment fidelity (and zero contamination) for a
health education session will be evidenced by 100% of
health education objectives and 0% of behavior therapy
objectives met. When a session is reviewed with less than
85% of treatment-specific objectives met and/or any evi-
dence of contamination (>0% other condition objectives
met), the auditor will inform the PI who will remediate
interventionist training as needed. This process will con-
tinue through all treatment waves so that counselor/edu-
cator drift can be swiftly corrected.
Treatment Fidelity of Group Weight Loss Sessions
Provider and auditor checklists were created for the group
weight loss visits to ensure that treatment objectives for
each group session are met in each condition. Contamina-
tion will be evident in group sessions if elements of
behavioral activation are being met during group sessions.
Group leaders will not be trained in or have expertise with
behavioral activation or any other therapeutic approaches
for depression. However, participants with depression
may spontaneously bring depression into the group dis-
cussion. Group leaders will emphasize that the purpose of
the groups is to help participants improve their lifestyle
habits, which can have a positive effect on stress and
depression. Group leaders will be trained to stay within
the protocol and not engage in problem-solving around
depression-specific issues. They also will notify the PI if a
participant requests further help, to determine whether a
referral is deemed necessary. As for individual visits, an
audited session with less than 85% of treatment-specific
objectives met and/or any evidence of contamination will
be brought to the attention of the PI who will remediate
interventionist training as needed.
Discussion
The present study aims to test whether sequencing behav-
ioral treatment for depression and behavioral weight loss
treatment produces greater weight loss than administering
standard weight loss treatment alone in depressed, obese
women. Research suggests that depressed individuals tend
to fair worse in weight loss interventions than their non-
depressed counterparts, perhaps because their depression
remains untreated and presents a barrier to behavior
change [2]. Behavioral activation involves increasing
activity, decreasing avoidance behaviors and changing
maladaptive coping strategies, all of which might facilitate
the dual goals of decreasing depression and increasing
weight loss.
Behavioral activation, cognitive-behavioral therapy, and
cognitive therapy were considered for combining with
weight loss treatment, but behavioral activation was
selected for several reasons. First, behavioral activation is
briefer than cognitive behavioral therapy [45] with effi-
cacy in as little as 8 sessions [29]. Second, behavioral acti-
vation is relatively uncomplicated compared to cognitive
therapies and so can be used with participants with vary-
ing levels of insight and intellectual capacity. Third, the
intense focus on increasing activity is appropriate to the
goals of treatment for both depression and weight loss.
The goal of behavioral activation is to substitute adaptive
coping behaviors for maladaptive ones. Weight loss could
be facilitated by helping the participant increase her arse-
nal of mood regulatory behaviors to break an overreliance
on eating for coping with negative moods/boredom and
to gradually adopt more physically active coping behav-
iors. Fourth, the focus on eliminating avoidance in behav-
ioral activation is relevant to both mood and weight.
Avoidance among obese participants can take the form of
excessive eating and prolonged sedentary activities (e.g.,
hypersomnia, TV, computer/internet use) and prevent the
participant from engaging in other more reinforcing and
active aspects of life.BMC Psychiatry 2008, 8:77 http://www.biomedcentral.com/1471-244X/8/77
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Multiple behavior change is touted as an economical and
efficient way of reducing health risk [51], however the
necessity of combining treatment for depression and
obesity goes beyond economy and efficiency. The proc-
esses maintaining the two disorders when they co-occur
may be so intertwined that improvements in one condi-
tion may be contingent on improvements in the other.
While combining weight loss and depression therapies
may seem warranted, administering two fairly intensive
treatments simultaneously may be too overwhelming for
patients who are physically and emotionally taxed. Pre-
liminary data revealed that a simultaneous approach is
feasible, strongly impacts depression, but may not lead to
greater weight loss compared to a weight loss intervention
that does not address depression [19]. The impact of
weight loss counseling might be improved if administered
once depressive symptoms have begun to subside. As
such, depression treatment will be administered prior to
intensive efforts towards weight loss. This approach may
not only be more clinically indicated, but also more cost-
effective since clinical efforts towards weight loss will be
administered during a "window of opportunity" when the
patient is better prepared to respond.
There are some limitations of the study. The intensity of
the treatment protocol may make adoption in practice set-
tings with limited resources difficult. However, since treat-
ment for depression is usually a reimbursable service, but
weight loss treatment is not, packaging depression and
weight loss treatment together may be a more affordable
option for many patients. Also, exclusion criteria limit
generalizability to at-risk populations such as people with
type 2 diabetes, severe depression, or people who are on
certain medications associated with weight gain. Once
efficacy is established, effectiveness studies with less strin-
gent exclusion criteria are needed to evaluate the impact
in real world settings.
Conclusion
While evidence-based treatments exist for both obesity
and depression separately, these disorders are frequently
comorbid and treatment approaches have not been estab-
lished for these disorders when they co-occur. This trial
attempts to promote weight loss in depressed, obese
women by administering behavioral activation treatment
for depression directly prior to an evidence-based weight
loss treatment. Given the high rates of psychological dis-
orders among individuals with obesity, research is needed
to understand the mechanisms linking psychological dis-
orders with obesity, as well as whether weight loss treat-
ment approaches that are tailored to the psychological
disorder improve both weight loss and mental health out-
comes.
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